SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?


To: Harold Engstrom who wrote (568)1/22/1998 2:29:00 PM
From: Scott  Read Replies (1) | Respond to of 1686
 
Sure. A lot can change in two months. Remember, in evaluating a drug you have to have BOTH efficacy and safety. CBM's press release only deals with efficacy. Sure, Tobin's abrupt dropping of OP-1 from his list of things in development could be an oversight. But it seems very consistent over the last few weeks.

Whether or not OP-1 is a dog, the pipeline is still terrific. It would be if only anti-CD40L were in it, but the mAb has good company.